A number of other brokerages have also commented on EVTCY. Deutsche Bank AG reiterated a neutral rating on shares of Evotec AG in a research note on Wednesday, May 3rd. Zacks Investment Research upgraded shares of Evotec AG from a hold rating to a buy rating and set a $17.00 price target on the stock in a research note on Tuesday, February 14th. Finally, DZ Bank AG reiterated a neutral rating on shares of Evotec AG in a research note on Friday, February 10th.
Shares of Evotec AG (NASDAQ:EVTCY) traded down 1.64% during mid-day trading on Friday, hitting $27.54. The stock had a trading volume of 1,057 shares. The stock has a market cap of $1.92 billion and a price-to-earnings ratio of 49.89. Evotec AG has a one year low of $7.80 and a one year high of $29.45. The firm has a 50 day moving average of $23.58 and a 200 day moving average of $17.15.
Evotec AG (NASDAQ:EVTCY) last announced its quarterly earnings results on Tuesday, March 28th. The company reported $0.32 EPS for the quarter. The company had revenue of $47.36 million during the quarter.
About Evotec AG
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.